about
Polymorphisms in the CYP2E1 and GSTM1 genes as possible protection factors for leprosy patientsClinical oxidative stress during leprosy multidrug therapy: impact of dapsone oxidationMolecular Epidemiology of Agents of Human Chromoblastomycosis in Brazil with the Description of Two Novel SpeciesLeprosy in Children.Clinic-epidemiological evaluation of ulcers in patients with leprosy sequelae and the effect of low level laser therapy on wound healing: a randomized clinical trial.Effects of immunomodulatory drugs on TNF-α and IL-12 production by purified epidermal langerhans cells and peritoneal macrophages.Spatial analysis spotlighting early childhood leprosy transmission in a hyperendemic municipality of the Brazilian Amazon regionInfluence of Genetic Ancestry on INDEL Markers of NFKβ1, CASP8, PAR1, IL4 and CYP19A1 Genes in Leprosy Patients.Spatial epidemiology and serologic cohorts increase the early detection of leprosyDrug and multidrug resistance among Mycobacterium leprae isolates from Brazilian relapsed leprosy patients.Development of natural culture media for rapid induction of Fonsecaea pedrosoi sclerotic cells in vitroHaplotypes of the IL10 gene as potential protection factors in leprosy patients.Chromoblastomycosis: an overview of clinical manifestations, diagnosis and treatment.Enzymatic isolation of Lacazia loboi cells from skin lesions of lobomycosis.High rates of undiagnosed leprosy and subclinical infection amongst school children in the Amazon Region.Field-friendly serological tests for determination of M. leprae-specific antibodies.Antioxidant factors, nitric oxide levels, and cellular damage in leprosy patients.Cyclosporine A treatment of leprosy patients with chronic neuritis is associated with pain control and reduction in antibodies against nerve growth factor.Fungal x host interactions in Chromoblastomycosis: what we have learned from animal models and what is yet to be solved.Methemoglobinemia and dapsone levels in patients with leprosy.TGF-beta plasma levels in chromoblastomycosis patients during itraconazole treatment.High anti-phenolic glycolipid-I IgM titers and hidden leprosy cases, Amazon region.Cutaneous localized annular chromoblastomycosis.Physalis angulata extract exerts anti-inflammatory effects in rats by inhibiting different pathways.In vitro cytokines profile and ultrastructural changes of microglia and macrophages following interaction with Leishmania.Description of electrophoretic and chromatographic hemoglobin profile of Rhinoclemmys punctularia.Phylogenomics and antimicrobial resistance of the leprosy bacillus Mycobacterium leprae.Are leprosy case numbers reliable?Anti-PGL-I seroepidemiology in leprosy cases: household contacts and school children from a hyperendemic municipality of the Brazilian Amazon.miRNome Expression Analysis Reveals New Players on Leprosy Immune Physiopathology.Evidence of zoonotic leprosy in Pará, Brazilian Amazon, and risks associated with human contact or consumption of armadillos.ChromoblastomycosisA Model for Trans-Kingdom Pathogenicity in Agents of Human ChromoblastomycosisEvaluation of Immunodiagnostic Tests for Leprosy in Brazil, China and EthiopiaUltrastructural characterization of melanosomes of the human pathogenic fungus Fonsecaea pedrosoiWhat do we actually know about leprosy worldwide?A New Prenylisoflavone from the Antifungal Extract of Leaves of Vatairea guianensis AublLeprosy Transmission: Still a ChallengeLeonine Facies: Lepromatous LeprosyCutaneous diffuse chromoblastomycosis
P50
Q28484397-3D2F938B-ED16-4CD6-B57B-E28F138FA1A3Q28538986-4133DBB1-F5AF-4C2C-8FCE-899C89B0942DQ28818529-22017499-0082-45F2-846B-C01139622DCDQ30234659-CC65A954-9153-40E1-9B98-10DF283E186AQ33653681-ADC2BB67-D51D-41D6-937D-A1259BC3BC83Q33806405-4613326A-A9B5-4B0D-AEA6-1CC26262D8B9Q35091843-8EAE6CBE-7271-47A8-AC99-1FB7B2FFBB8DQ35772562-9B44F986-96E0-4CF3-942E-93810C6201AAQ35843218-6144164C-2C21-4ADF-85A5-7123B7CB0333Q36023028-5BAA3017-B8C3-4210-849E-9B7408C6D3CDQ36957958-5373D36D-2EBE-4B9B-8778-786CB48C56AEQ37252377-FE43D8E3-232C-41B3-8363-0A1EF76FB711Q37351604-9A9E6098-313E-466B-9EAB-72A9B02B4CA4Q39425089-5757A9FB-F448-4A90-B2ED-FAC32BA9BD87Q40083457-7C7AA7DE-1772-4C5E-A533-3128F23F544AQ40085030-999BC346-163D-4FFA-9E10-EFBFC943ADB5Q42239469-B4FD5679-7196-4D30-9B74-9E71E66EC673Q42594771-ED47FF41-68C3-4484-B355-8165DB7950F9Q42720012-45CF8EF1-B0FE-497A-B95B-EF45ED564F82Q42909662-0771698C-4FAE-473B-A3D0-37793F895761Q42973673-09F1E084-81A0-4C63-995F-DFF14605E610Q43180373-F5FD6124-9FFD-43A9-A865-8D82FDAD4D5FQ46411055-8B58D725-A832-493A-81CC-0445B28BEE81Q46566479-92B59FFD-3969-4F7C-BA10-86CF6423519EQ46907817-03CB1572-A88A-4195-BA8A-C84434C62228Q46938121-9ABA99A3-191F-4094-9920-9630C743792CQ48171730-DC218321-336A-43BA-9125-E4A96BA6CFF2Q50140271-23AFABF6-A5EE-4918-9B73-ABC682F015C4Q50955967-4D9ECF82-353C-48BF-8B1C-7B2404578052Q51415628-8FFF8A42-7C45-4253-B1FC-0C3EF86A29A6Q55514433-4D79B4BD-D4EA-4A54-ACA4-CF10F1B85E1EQ56915677-C41ED4A5-BD69-43F0-A5D8-E700A5D4DAA4Q57816791-0849A663-01B7-454F-B567-4FBB6B83A6C4Q60301464-1E2C1D63-2259-402F-9F9C-8127CE347BA1Q62032302-5E358C5D-FB6F-4A6B-B3F9-7F14D4BA59BDQ62743066-BA31C19A-7B85-4FD9-8074-EDDF6FB7CF06Q62743170-A1681591-2C19-49E4-AF4A-244C113DA11CQ62743182-70B91314-81ED-4803-9816-EDFA845A8D49Q62743186-FD189D07-C6D1-41B6-8F98-049104A67970Q62743200-A9BD4825-E23F-4D35-9CB5-C2649A1C4B79
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Claudio Guedes Salgado
@ast
Claudio Guedes Salgado
@en
Claudio Guedes Salgado
@es
Claudio Guedes Salgado
@nl
type
label
Claudio Guedes Salgado
@ast
Claudio Guedes Salgado
@en
Claudio Guedes Salgado
@es
Claudio Guedes Salgado
@nl
prefLabel
Claudio Guedes Salgado
@ast
Claudio Guedes Salgado
@en
Claudio Guedes Salgado
@es
Claudio Guedes Salgado
@nl
P106
P1153
8522894300
P21
P31
P496
0000-0003-3961-7764